Aranesp

Aranesp
Name	Aranesp

Aranesp is a medication used to treat anemia associated with chronic kidney disease and certain types of cancer, such as breast cancer, lung cancer, and lymphoma, particularly in patients receiving chemotherapy with cisplatin, carboplatin, or doxorubicin. It is manufactured by Amgen and works by stimulating the production of red blood cells in the bone marrow, similar to epoetin alfa and darbepoetin alfa. Aranesp has been compared to other erythropoiesis-stimulating agents (ESAs) like Mircera and Retacrit in terms of its efficacy and safety profile, as evaluated by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Introduction

Aranesp is a recombinant human erythropoietin (EPO) analogue, which is a glycoprotein that plays a crucial role in the production of red blood cells by stimulating the bone marrow. It is used to treat anemia caused by chronic kidney disease, HIV infection treated with zidovudine, and certain types of cancer, such as non-small cell lung cancer and small cell lung cancer, particularly in patients receiving chemotherapy with paclitaxel or docetaxel. The medication has been studied in various clinical trials, including the CREATE and CHOIR trials, which compared its efficacy and safety to placebo and other ESAs, such as Epogen and Procrit. Aranesp has also been evaluated by the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) for its use in the treatment of anemia in patients with chronic kidney disease.

Medical_uses

Aranesp is used to treat anemia associated with chronic kidney disease in patients on dialysis or not on dialysis, such as those with end-stage renal disease (ESRD) or chronic kidney disease stage 5. It is also used to treat anemia caused by chemotherapy in patients with non-myeloid malignancies, such as breast cancer, ovarian cancer, and lymphoma, particularly in patients receiving chemotherapy with anthracyclines or taxanes. Additionally, Aranesp has been used to treat anemia in patients with HIV infection treated with zidovudine, as well as in patients with myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), such as polycythemia vera and essential thrombocythemia. The medication has been compared to other ESAs, such as Aranesp and Mircera, in terms of its efficacy and safety profile, as evaluated by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Mechanism_of_action

Aranesp works by stimulating the production of red blood cells in the bone marrow by binding to the erythropoietin receptor (EPO-R) on the surface of erythroid progenitor cells. This binding causes a cascade of intracellular signaling events that ultimately lead to the production of red blood cells. Aranesp has a longer half-life than epoetin alfa and darbepoetin alfa, which allows for less frequent dosing, as evaluated by the National Institutes of Health (NIH) and the World Health Organization (WHO). The medication has been studied in various clinical trials, including the CREATE and CHOIR trials, which compared its efficacy and safety to placebo and other ESAs, such as Epogen and Procrit. Aranesp has also been evaluated by the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) for its use in the treatment of anemia in patients with cancer.

Side_effects

The most common side effects of Aranesp include injection site reactions, such as pain, redness, and swelling, as well as headache, fatigue, and nausea. More serious side effects can include thrombosis, stroke, and myocardial infarction, particularly in patients with a history of cardiovascular disease, such as hypertension and hyperlipidemia. Aranesp can also increase the risk of tumor progression and tumor recurrence in patients with cancer, particularly in those with breast cancer and lung cancer. The medication has been compared to other ESAs, such as Mircera and Retacrit, in terms of its safety profile, as evaluated by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

History

Aranesp was first approved by the US Food and Drug Administration (FDA) in 2001 for the treatment of anemia associated with chronic kidney disease. It was later approved for the treatment of anemia caused by chemotherapy in patients with non-myeloid malignancies in 2002. The medication has been marketed by Amgen and has been used to treat millions of patients worldwide, including those in the United States, Europe, and Japan. Aranesp has been evaluated by the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) for its use in the treatment of anemia in patients with chronic kidney disease.

Pharmacology

Aranesp is a recombinant human erythropoietin (EPO) analogue that is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) cell line. It has a molecular weight of approximately 37,000 daltons and a half-life of approximately 130 hours, which allows for less frequent dosing, as evaluated by the National Institutes of Health (NIH) and the World Health Organization (WHO). The medication is administered via subcutaneous injection or intravenous injection and is available in various dosages, including 25 micrograms, 40 micrograms, and 60 micrograms. Aranesp has been compared to other ESAs, such as Epogen and Procrit, in terms of its pharmacokinetic and pharmacodynamic properties, as evaluated by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Category:Medications